Form 4: Crinetics Pharmaceuticals CFO Marc Wilson Reports Acquisition of Restricted Stock Units and Stock Options
SEC Form 4 Filing
CFO of Crinetics Pharmaceuticals, Marc Wilson, reports the acquisition of 25,500 restricted stock units and 95,500 stock options.
Summary
- On March 4, 2024, Marc Wilson, CFO of Crinetics Pharmaceuticals, reported acquiring 25,500 shares of common stock through restricted stock units.
- These restricted stock units vest 25% annually, starting March 15, 2025.
- Wilson also acquired 95,500 stock options with an exercise price of $43.51.
- These options vest in 48 equal monthly installments from March 4, 2024, and expire on March 3, 2034.
- Following these transactions, Wilson directly owns 121,555 shares of Crinetics Pharmaceuticals common stock and 95,500 stock options.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The filing reflects standard executive compensation practices and insider confidence, but doesn't contain any groundbreaking news.
Positives
- The acquisition of restricted stock units and stock options suggests confidence in the company's future performance from the CFO.
Future Outlook
The vesting schedules for the restricted stock units and stock options indicate a long-term incentive plan for the CFO, aligning his interests with the company's performance over the coming years.
Industry Context
Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's securities. These filings are closely watched by investors for signals about management's confidence in the company's prospects.
Comparison to Industry Standards
- Stock option and restricted stock unit grants are common compensation practices in the pharmaceutical industry, used to incentivize executives and align their interests with shareholders.
- The vesting schedules and exercise prices are typical for such grants, designed to reward long-term value creation.
- Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize similar equity-based compensation plans for their executives.
Stakeholder Impact
- The equity grants align the CFO's interests with those of shareholders, incentivizing him to drive long-term value creation.
- Employees may view the grants as a positive sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 03/04/2024 | Date of transaction: Acquisition of restricted stock units and stock options. |
| 03/04/2024 | Vesting commencement date for stock options. |
| 03/06/2024 | Date of signature for the Form 4 filing. |
| 03/15/2025 | First vesting date for the restricted stock units (25%). |
| 03/03/2034 | Expiration date for the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.